HYDERABAD/BENGALURU (Reuters) – Sun Pharmaceutical, India’s largest drugmaker by revenue, reported first-quarter profit above analysts’ estimates on Thursday, helped by strong sales of its chronic therapy and specialty dermatology drugs in the key U.S. and domestic markets.
The Mumbai-based company’s net profit rose 40% to 28.36 billion rupees ($339 million) in the three months ended June 30, beating analysts’ average estimate of 24.78 billion rupees, according to LSEG data. ($1 = 83.7040 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Savio D’Souza)
